Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

Inclusion Criteria: * Patient following allogeneic SCT * Patient with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after SCT * Absolute neutrophil count (ANC) ≥1000 cells/µL on 2 consecutive follow-ups within 10 days before randomization * Patient has a creatinine clearance of ≥25 mL/min (calculated by the Cockcroft-Gault formula, see Part I Section 6.1.2) with evidence of improving renal function, * None or gastrointestinal graft-versus-host disease (GVHD) up to grade 2 Exclusion Criteria: * Patient has a suspected or diagnosed CMV disease * Patient has received syngeneic SCT * Patient who received an investigational medicinal product (IMP) within the last 30 days prior to screening or who is simultaneously participating in another clinical study with an IMP * Patient with a body weight \<50 kg or \>95 kg, * Patient has received anti-CMV therapy within the past 30 days prior to screening (the use of acyclovir, valacyclovir, or famciclovir is permitted) * Patient who has participated in this study before, * Patient who shows a neutropenia, thrombocytopenia, or anemia within 10 days before or at the time point of randomization as following: * The ANC is \<1000 cells/μL on 2 consecutive follow-ups, or * A platelet count of ≥25000/μL can not be achieved/maintained with platelet transfusions * A hemoglobin level of ≥8g/dL can not be achieved/maintained by red blood cell transfusions